Insider Shareholders with Direct Ownership of Nuvectis Pharma, Inc. (NVCT)
This section provides a comprehensive overview of the insiders with direct ownership of Nuvectis Pharma, Inc. (NVCT). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Nuvectis Pharma, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Ron Bentsur
Chairman & CEO |
955,465 | 0 | 3,520,924 $19.3 Million | 72 |
Jan 02, 2025
Added 6.63%
|
|
Marlio Charles Mosseri
> 10% Shareholder |
231,824 | 0 | 2,612,000 $14.3 Million | 20 |
Dec 13, 2024
Added 0.65%
|
|
Enrique Poradosu
Chief Science & Business Off |
463,270 | 0 | 1,656,319 $9.09 Million | 10 |
Jan 02, 2025
Added 8.3%
|
|
Shay Shemesh
Chief Dev. & Ops. Officer |
466,399 | 0 | 1,643,068 $9.02 Million | 20 |
Jan 02, 2025
Added 8.37%
|
|
Michael J. Carson
Vice President, Finance |
114,373 | 2,755 | 138,918 $762,659 | 4 |
Jan 02, 2025
Added 26.85%
|
|
Kenneth Hoberman
Director |
54,000 | 0 | 103,140 $566,238 | 3 |
Jun 13, 2024
Added 22.53%
|
|
Matthew L. Kaplan
Director |
51,000 | 0 | 83,760 $459,842 | 3 |
Jun 13, 2024
Added 26.37%
|
|
James F Oliviero Iii
Director |
48,000 | 0 | 57,828 $317,475 | 2 |
Jun 13, 2024
Added 34.16%
|